CancerFax Partners with Global Oncology to Access China's Cancer Trial Network

A meaningful step for CancerFax, and one I have wanted to write about for a while.

We have entered into a collaboration with Global Oncology — a leading clinical research organization in China, a group actively involved in running and coordinating cancer clinical trials across the country. For us, this is not a logo on a slide. It is direct, working access to one of the most active trial ecosystems in oncology today.

Why this matters for patients

China runs an enormous and fast-moving body of cancer trials, particularly in cell therapy, gene therapy, and precision oncology. CAR-T, CAR-NK, TIL, and targeted approaches are being tested here at a volume and pace that is exceptionally difficult to match anywhere else.

The problem has never been that these trials do not exist. The problem is that a patient in Tashkent, Bucharest, or Manila has almost no way to know which ones are open, which ones fit their disease, and whether they are even eligible.

What this collaboration actually does

This collaboration closes part of that gap. It gives our clinical team current, structured visibility into advanced and recruiting trials across leading Chinese centers — so that when a complex case reaches us, China is a real option we can evaluate properly, not a guess.

What this is — and what it is not

I want to be honest.

It does not mean a trial for everyone. Eligibility is strict and biology decides.

What it does mean is that no patient working with us will be left unaware that an advanced option existed somewhere they never thought to look.

To the team we are now working with — thank you for taking international patients seriously. That is rarer than it should be.

More to come on how patients and referring physicians can use this.